Drug Trial Radar · NCT07227636
A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
284
Planned (sponsor's estimate)
Start
Nov 7, 2025
Primary completion
Nov 2030
Study completion Nov 2030
Sponsor
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Agenus Inc.
- First posted
- Nov 13, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The researchers are doing this study to find out whether the combination of botensilimab and balstilimab (BOT/BAL), followed by balstilimab alone, is an effective treatment for people with microsatellite stable (MSS) colorectal cancer or colorectal liver metastases (CRLM) who have measurable residual disease (MRD) after standard treatment with surgery and chemotherapy or total neoadjuvant therapy (TNT).
Conditions
- Colorectal Cancer
- Rectal Cancer
Interventions
BotensilimabDrug
All patients will receive botensilimab IV on day 1 of the 42 day cycle for 4 doses
BalstilimabDrug
All patients will receive balstilimab IV on days 1, 15, and 29 of the 42 day cyclePatient then continues balstilimab alone for an additional two cycles IV on days 1, 15, and 29 of the 42 day cycle.
PlaceboOther
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Rate of ctDNA clearance (Cohort 1a)Time frame: 6 months
- Rate of ctDNA clearance (Cohort 1b)Time frame: 6 months
- Recurrence-free survival (RFS) (Cohort 2a)Time frame: 1 year
- Recurrence-free survival (RFS) (Cohort 2b)Time frame: 1 year
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)
Basking Ridge, New Jersey · Recruiting
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)
Middletown, New Jersey · Recruiting
Memorial Sloan Kettering Bergen (Limited Protocol Activities)
Montvale, New Jersey · Recruiting
Memorial Sloan Kettering Commack (Limited Protocol Activities)
Commack, New York · Recruiting
Memorial Sloan Kettering Westchester (All Protocol Activities)
Harrison, New York · Recruiting
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York, New York · Recruiting
Memorial Sloan Kettering Nassau (Limited Protocol Activities)
Rockville Centre, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.